Lung Cancer Symptom Assessment and Management Intervention
Phase 2
Completed
- Conditions
- Lung Cancer
- Registration Number
- NCT00852462
- Lead Sponsor
- Dana-Farber Cancer Institute
- Brief Summary
The purpose of this study is to develop and test the usability of a computerized symptom assessment and management intervention system in a laboratory setting (phase I) and its feasibility in a clinical setting in a group randomized trial (phase II).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 179
Inclusion Criteria
- HCPs: attending physician, thoracic medical oncologist, expected to work in the setting for at least 2 years.
- Patients: 21 years of age or older; diagnosis of Stage IIIA, IIIB, IV non-small cell lung cancer OR limited or extensive stage small cell lung cancer; receiving care in the out-patient setting; receiving treatment with chemotherapy +/- additional therapies; English speaking.
Exclusion Criteria
- Patients: Any patient who needs emergent care, routine visits scheduled less than once a month
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method % completion of intervention use and adherence to suggested symptom management strategies. 2 years
- Secondary Outcome Measures
Name Time Method Health-related quality of life 6 months
Trial Locations
- Locations (2)
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Boston Medical Center
🇺🇸Boston, Massachusetts, United States
Dana-Farber Cancer Institute🇺🇸Boston, Massachusetts, United States